MIMETAS US, INC

Gaithersburg, MD · Medtech · Acquired

NephroPlate, a 3D kidney-on-a-chip microfluidic platform for modeling human kidney disease and drug screening

Grants
$6.5M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies$236,779
Federal grantDepartment of Health and Human Services · Phase II · Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies$1,993,146
Federal grantDepartment of Health and Human Services · Phase II · Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies$993,146
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1266CytoTronics, Inc.—$14M
1267NanoSpy, Inc.——
1268Lento Bio, Inc—$5.0M
1269MIMETAS US, INC——
1270Whisker Labs, Inc.—$11M
1271QUICKSILVER BIOSCIENCES, INC.——
1272RD RESEARCH TECHNOLOGY USA LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.